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Abstract: Industrial chemical companies have taken advantage of enzymes for the production of 
pharmaceuticals by means of nonselective and selective transformations. This review covers recently 
published chemoenzymatic synthesis of important drugs, focusing on the production of the desired 
targets with high to excellent yields. Remarkably, biocatalysts have allowed the development of 
asymmetric processes through different strategies, providing efficient access to challenging substrates 
that are difficult to obtain by traditional chemical methods. Thus, the action of different classes of non 
hydrolytic enzymes has been covered, including a wide number of oxidoreductases, lyases and 
transferases. The importance of using enzymes with synthetic purposes under mild reaction conditions 
is fully demonstrated in the production of active pharmaceutical ingredients and other organic 




The use of biotransformations for synthetic purposes nowadays plays an important role in synthetic 
chemistry.1,2 Enzymes have shown a high level of reactivity and exquisite selectivity catalyzing 
chemo-, regio- and stereoselective transformations under mild reaction conditions.3,4 Thus, their 
application can contribute to existing methods for accessing both non-chiral and optically active 
chemicals.5-7 This fact has led to the incorporation of enzymatic catalysis to the synthetic organic 
expert's toolbox, making the development of highly selective transformations possible.8,9 Additionally, 
the advances in protein engineering techniques have broaden the number of enzymes available, and 
consequently the possibilities of finding the best enzyme for a given process.10 This is especially 
relevant when this knowledge is applied at industrial level, and many biotechnology and chemical 
companies have taken advantage of the activities displayed by enzymes because of their low 
environmental impact in terms of energy, raw material and waste production.11-17 
Nowadays the development of catalytic methods inside the pharmaceutical industry is well established, 
including at large-scale.18,19 The pursuit of novel drug candidates is feasible through a wide panel of 
organic reactions,20 most of which can also be developed using enzymes. In this context, biocatalysis 
has emerged as a powerful tool for the selective modification of final targets or precursors through 
different reactions.21-27 
In this review, the authors aim to provide a broad and representative selection of articles published in 
the last six years dealing with the chemoenzymatic synthesis of highly valuable organic compounds 
with applications in medicinal chemistry. The role of native enzymes from the class of oxidoreductases, 
lyases and transferases for the production of pharmaceuticals and compounds with interesting 
biological profiles is discussed here. For simplicity, noteworthy achievements made when using 
evolved enzymes have not been included, an insight into further improvements and a comparison with 
the use of wild-type enzymes being given in just some cases. The synthetic strategies described have 
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been categorised according to the class of enzymes employed in the overall process. The strict 
requirements in terms of the degree of enantiopurity for life-science products have led us to pay special 
attention towards those steps that facilitate the introduction of chirality or stereodiscrimination for the 
formation of single enantiomers.28 
 
2. Use of oxidoreductases for the synthesis of chiral drugs. 
Because of the wide panel of redox enzymes (EC 1)29 present in nature, this class of biocatalysts 
offers a myriad of possibilities in synthetic chemistry. The development of oxidation and reduction 
processes has allowed the preparation of multiple families of compounds by means of whole cells 
biotransformations or using purified enzymes.30-32 Oxidoreductases require the presence of the β-
nicotinamide adenine dinucleotide as a cofactor. This exists in the oxidized form as a phosphorylated 
(NADP+) or non phosphorylated structure (NAD+), as well as in its reduced form (NAD(P)H). This 
ubiquitous redox cofactor is present in living cells involved in many cellular processes, such as electron 
transport and oxidative phosphorylation. The high cost of the nicotinamide cofactor makes its in situ 
regeneration necessary in preparative enzymatic synthesis when using the purified enzyme, so 
alternatively the development of whole cell systems has been extensively explored in the literature. 
In this section examples of redox processes for the synthesis of pharmaceuticals will be described, 
paying special attention to the action of alcohol dehydrogenases (ADHs) and enereductases for 
bioreduction processes,33 alcohol oxidases, monoamino oxidases, monoamino acid oxidases and 
laccases for oxidative processes, and finally oxygenases for the introduction of oxygen in a given 
molecule. 
Most of the examples reported in the literature involve the reduction of carbonyl groups, the oxidation 
of alcohol functionalities, and the hydroxylation of non activated positions. However, redox enzymes 
are also valuable catalysts for the production of chiral amines and amino acids, leading to alternative 
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reductive amination reactions where the starting material and final product are identical to those in 
transaminase-catalyzed reactions. In the case of redix enzymes, amine and amino acid dehydrogenase 
(AH and AAH) are efficient enzymes for the transformation of ketones into amines or amino acids as 
occurs with transaminases from the transferase class. As with other types of biocatalysts, molecular 
biology34 and directed evolution techniques35 have led to the development and discovery of more 
stable and selective dehydrogenases for the synthesis of optically active amines. 
 
2.1. Alcohol dehydrogenases. 
Also known as ketoreductases or carbonyl reductases, they are probably the most ubiquitous enzymes 
in nature. Their ability to stereoselectively reduce carbonyl groups makes them attractive tools for the 
synthesis of enantiopure alcohols,36-39 and the pharmaceutical industry has taken clear advantage of 
this.40 In addition to the vast number of native ADHs, their substrate specificity and stereochemical 
outcome can also be modified by the application of a series of advanced techniques involving the 
production of recombinant species with one or more catalysts in an adequate host,41-48 or through the 
development of directed evolution methods.49 In this section, we summarise the action of ADHs for 
the bioreduction of ketones in order to produce valuable intermediates and final compounds with 
interesting applications in medicinal chemistry. 
The use of Saccharomyces cerevisiae CGMCC 2266 has allowed the asymmetric reduction of 3-
chloropriophenone to produce (S)-3-chloro-1-phenylpropanol, a versatile intermediate in the synthesis 
of antidepressant agents such as Fluoxetine, Atomoxetine and Nisoxetine (Scheme 1).50 The 
immobilization of the cells in calcium alginate provided benefits in terms of conversion and 
stereoselectivity, the final product being obtained in 80% conversion and enantiopure form. 
Significantly, after being reused three times, the immobilized enzyme retained approximately 60% of 
its catalytic activity with complete stereopreference. González and co-workers reported the use of five 
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endophytic yeast strains isolated from edible plants for the bioreduction of the same chlorinated 
intermediate or alternatively the 3-azido-1-phenylpropanone, finding modest levels of selectivity and 
generally low yields due to the formation of side-reaction products because of the presence of the 
catalytic activities in the enzyme preparations.51 Other enzymes such as ADH from Rhodococcus 
ruber (ADH-A) and ADH from Thermonoanaerobacter sp. (ADH-T), available from different 
commercial sources, have also served for the production of Fluoxetine intermediates as described by 
Gotor52 and Berkowitz,53 who also described the use of horse liver alcohol dehydrogenase (HLADH) 
or Candida parapsilosis alcohol dehydrogenase (CP-ADH) for the quantitative production of an 
enantiopure Aprepitant intermediate, of a human neurokin-1 antagonist, and of Talampanel, used for 
the treatment of epilepsy. 
 
Scheme 1. Asymmetric bioreduction of 3-chloropropiophenone for the production of antidepressant 
intermediates. 
Miconazole and Econazole are two potent antifungal agents that are administrated in patients as 
racemates. The chemoenzymatic asymmetric synthesis of all four of their enantiomers was studied by 
means of lipase-catalyzed acylation of the corresponding racemic alcohols and the ADH-mediated 
reduction of 2-halogen-1-(2,4-dichlorophenyl)ethanones, the best results being found for the purified 
enzymes ADH-T and ADH-A in the formation at 30 ºC after 24 h of enantiopure (R)-2-chloro-1-(2,4-
dichlorophenyl)ethanol, a versatile precursor of the drugs with (R)-configuration (Scheme 2).54 
Unfortunately, the (S)-alcohol was isolated in low conversions with other ADHs tested, so for the 




Scheme 2. Asymmetric bioreduction of 2-chloro-1-(2,4-dichlorophenyl)ethanone for the synthesis of 
Miconazole and Econazole enantiomers. 
 
The bioreduction of other -chloroacetophenone derivatives also gave excellent results in this case of 
the synthesis of an (R)-tertbutaline hydrochloride intermediate, a potent 2-adrenoceptor-stimulating 
agent (Scheme 3).55 The yeast Williopisis californica JCM 3600 in whole cell form stereoselectively 
reduced the carbonyl group to obtain the desired (R)-alcohol in 98% ee and 80% isolated yield, the 
cofactor regeneration system being improved by adding glycerol. 
 
Scheme 3. Asymmetric bioreduction of a substituted -chloroacetophenone for the synthesis of (R)-
tertbutaline hydrochloride. 
 
Odanacatib is an active and selective cathepsin K inhibitor used in the treatment of postmenopausal 
osteoporosis. Recently, Souza and co-workers described the development of a chemoenzymatic process 
for the preparation of an Odanacatib precursor under continuous flow conditions, once the 
overexpressed ADH-A in E. coli had been found as a selective biocatalyst for the reduction of the key 
intermediate 1-(4-bromophenyl)-2,2,2-trifluoroethanone (Scheme 4).56 The desired enantiopure (R)-1-
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(4-bromophenyl)-2,2,2-trifluoroethanol was recovered with 98% yield after 2 h in the supernatant, and 
subsequently subjected to a Suzuki-Miyaura palladium-catalyzed coupling. 
 
Scheme 4. Chemoenzymatic synthesis of Odanacatib involving the ADH-catalyzed bioreduction of 1-
(4-bromophenyl)-2,2,2-trifluoroethanone. 
 
Rivastigmine is an acetylcholinesterase inhibitor that acts selectively in the brain. It possesses a 
carbamate functionality, the (S)-enantiomer having applications in dementia caused by Parkinson’s 
disease. A crude ADH from Baker’s yeast has been found to catalyze the stereoselective reduction of 
N-ethyl-N-methyl carbamoyl acetophenone at 50-g scale, affording the enantiopure (S)-alcohol 
precursor in 95% isolated yield at 30 ºC (Scheme 5).57 
 
Scheme 5. Synthesis of a (S)-Rivastigmine intermediate through a bioreduction process. 
 
Ezetimibe marketed as Zetia or Ezetrol is employed in the treatment of patients with coronary diseases, 
inhibiting the adsorption of cholesterol and related sterols. Its enzymatic synthesis was achieved by 
diastereoselective bioreduction of 1-(4-fluorophenyl)-(3R)-[3-oxo-3-(4-fluorophenyl)-propyl]-(4S)-(4-
hydroxyphenyl)azetidin-2-one using the Rhodococcus fascians MO22 microorganism in whole cell 
form (Scheme 6).58 After optimization of the reaction conditions, a 95% conversion into the desired 
diastereoisomer was attained after 24 h at 30 ºC. 
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Scheme 6. Enzymatic synthesis of Ezetimbe. 
 
Eslicarbazepine acetate, also known as Aptiom, Zebinix or Exalief, is a third-generation drug belonging 
to the class of carbamazepines with application in the treatment of epilepsy, neuralgia and other brain 
disorders. Resting cells of an ADH from Pichia methanolica were able to stereoselectively reduce the 
ketone intermediate (Scheme 7), providing the immediate (S)-alcohol precursor.59 For this purpose, an 
exhaustive optimization was performed including reaction parameters such as  the glucose present (1-
7%), substrate concentration (0.5-3.0 g/L), temperature (20-40 ºC), orbital shaking (100-200 rpm) and 
reaction medium. Remarkably, hexane was found as a suitable immiscible organic cosolvent for the 
isolation of the desired enantiopure alcohol in >85% conversion using a 2.5-g scale reaction. 
 
Scheme 7. Bioreduction of an Eslicarbazepine acetate precursor using an ADH from Pichia 
methanolica. 
 
The production of enantiopure profens such as Ibuprofen or Naproxen is highly appealing as they 
possess different biological profiles. The development of dynamic reductive kinetic resolutions for the 
production of these drugs has been possible starting from the corresponding racemic aldehydes using 
archeal thermophiles from Sulfolobus solfataricus60 or HLADH.61 (S)-2-Arylpropanols were obtained 
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in excellent yields and selectivities through ADH-catalyzed dynamic kinetic resolutions (DKRs) of the 
corresponding 2-arylpropanals (Scheme 8). 
 
Scheme 8. Dynamic reductive kinetic resolutions of 2-arylpropanals for the synthesis of profen 
derivatives. 
 
Loxoprofen belongs to the profen class and possesses non-steroidal anti-inflammatory properties. Its 
synthesis has been possible by using two independent enzymatic steps (Scheme 9). Firstly, the 
enzymatic kinetic resolution of the corresponding racemic alcohol was achieved using 8 equiv. of vinyl 
acetate and PSL as biocatalyst in iPr2O.
62 After convenient chemical modification, a series of 
microbial ketoreductases were tested in the diasteroselective reduction of a ketoacid intermediate, 
excellent discrimination being found for the formation not only of the desired trans-active Loxoprofen 
form with growing cells from Geotrichum candidum NBRC 4597 (20:1 dr in 78% isolated yield), but 




Scheme 9. Chemoenzymatic synthesis of Loxoprofen. 
 
Interestingly, the combination of an ADH such as HLADH and enoate reductases from the family of 
Old Yellow Enzymes (OYEs) has been applied for the reduction of ,-unsaturated aldehydes and 
ketones with excellent selectivities,63 providing access to optically active alcohols with different 
configurations. These are precursors in the synthesis of pharmaceuticals such as Ebalzotan, Robalzotan 
and Rotigotine (Scheme 10). 
 
Scheme 10. Combination of enoatereductases and ADHs in the bioreduction of ,-unsaturated 




Also known as enoate reductases (ERs), this class of redox enzymes is responsible for the bioreduction 
of C=C bonds of activated organic compounds such as prochiral ,-unsaturated ketones, aldehydes, 
carboxylic acid derivatives, and nitroalkenes,64-66 and possesses the same restrictions of cofactor 
dependency as previously seen with ADHs. The synthesis of anti-diabetic Tesaglitazar and 
Navaglitazar intermediates has been described by Gatti and co-workers through bioreduction of ,-
unsaturated aldehydes using native Baker’s yeast (BY)67 or the nicotinamide-dependent flavoproteins 
OYEs.68 BY led to the optically active hydroxy ethers, while the cloned, overexpressed and finally 
purified OYEs allowed the preparation of the optically active aldehydes that were reduced to alcohols 
using an ADH (Scheme 11).69 
 
Scheme 11. Use of enoate reductases for the synthesis of Tesaglitazar and Navaglitazar. 
 
The enereductase YqjM from Bacillus subtilis in lyophilized form has been applied in the bioreduction 
of methyl-2-phenyl acrylate.70 After an exhaustive optimization of the reaction conditions in terms of 
type of buffer and cosolvent, a system composed of a 20 mM phosphate buffer pH 7.0 and 1% of 2-
methyltetrahydrofuran was found to produce the desired ester in excellent conversion, 77% isolated 
yield and enantiopure form (Scheme 12). These conditions were later applied to a panel of substrates 
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including the synthesis of (R)-Flurbiprofen methyl ester, so the methyl 2-(3-fluoro-4-
hydroxyphenyl)acrylate was stereoselectively reduced in moderate yield (68%). 
 
Scheme 12. Synthesis of (R)-profen derivatives using enereductase YqjM from Bacillus subtilis. 
 
The synthesis of Pregabalin, a lipophilic -aminobutyric acid (GABA) has been developed by means of 
the bioreduction of (E)-ethyl 5-methyl-3-cyano-2-hexanoate using an ER from Lycopersicon 
esculentum overexpressed in E. coli (Scheme 13).71 The preparative reaction proceeded smoothly in 
the formation of the enantiopure alkane after 96 h. The evolution of native enzymes towards more 
active and selective mutants has allowed the efficient synthesis of other Pregabalin intermediates.72,73 
 
Scheme 13. Chemoenzymatic synthesis of Pregabalin using an enoate reductase. 
 
2.3. Alcohol oxidases, monoamino oxidases, monoamino acid oxidases and berberines. 
 
Enzymatic oxidation reactions have been traditionally explored less than their reverse reduction 
processes because of a series of inconveniences such as the destruction of chiral centers, unfavoured 
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thermodynamic equilibria, and high pHs for the development of efficient transformations. 
Nevertheless, oxidases provide an elegant regio-, chemo- and stereoselective access to broad families 
of organic substrates including, among others, ketones, aldehydes and imines, by means of single or 
multi-step transformations.74,75 Some examples are presented here in the search for sustainable routes 
to biologically active compounds. 
Enantiopure vicinal diols are useful building blocks for drug synthesis. In this context, Li and co-
workers developed an efficient methodology for the oxidative resolution of a series of 1,2-diols 
including 3-O-benzylglycerol, 1-(4-chlorophenyl)-1,2-ethanediol, 1-(4-methylphenyl)-1,2-ethanediol 
and 1-(4-phenyl)-1,2-ethanediol, all of them being key fragments of important pharmaceuticals. The 
regio- and stereoselective oxidation was achieved using Sphingomonas sp. HXN-200 microbial cells, 
yielding the corresponding optically active diols in excellent optical purity (>98% ee), and the hydroxy 
carboxylic acids as overoxidized products through the formation of the aldehydes as intermediates 
(Scheme 14).76 
 
Scheme 14. Regio- and stereoselective oxidation of racemic 1,2-diols using Sphingomonas sp. 
 
Functionalized lactones are also important intermediates in the synthesis of biologically active 
compounds, and their preparation is favoured starting from 1,4- and 1,5-diols. Molinari and co-workers 
reported the oxidation of 1-alkyl-1,4-butanediols into -lactones with moderate selectivities but good 
yields using Acetobacter aceti MIM 2000/28 as growing cells or with cells centrifuged and 
resuspended in phosphate buffer.77 The formation of the corresponding lactols was observed and 
validated by the synthesis of Drospirenone, a synthetic steroid used as a hormonal contraceptive, 
starting from 6,7;15,16-dimethylene-3-oxo-17-pregn-4-en-21,17-carbolactol (Scheme 15). 
 14 
 
Scheme 15. Synthesis of Drospirenone by Acetobacter aceti-catalyzed oxidation. 
 
Monoamino oxidases (MAO) and monoamino acid oxidases (MAAO) are two types of versatile 
oxidative enzymes which act towards amino groups in amines and amino acids, respectively, and open 
new possibilities for subsequent in situ chemical or enzymatic reduction leading to efficient 
deracemization processes. Thus, the isolation of an enantiopure compound is possible, theoretically, in 
100% yield. The modification of their amino acid sequence through directed evolution techniques has 
allowed a spectacular advance in this field, especially for MAO enzymes, leading to the preparation of 
pharmacologically active compounds or amine-based intermediates such as prolyl peptides,78,79 
Telaprevir,80 Crispine A,81 Boceprevir intermediates,82 tetrahydro--carbolines83 and different 
alkaloid natural products.84 Regarding the use of wild-type enzymes, Patel and co-workers described 
three independent strategies for the biocatalytic production of (S)-2-amino-3-(6-o-tolylpyridin-3-
yl)propanoic acid, a key intermediate of an anti-diabetic drug candidate, using a monoamino acid 
oxidase from Trigonopsis variabilis expressed in Escherichia coli (Scheme 16).85 On one hand, the 
authors reported the selective oxidation of the racemic amine to the α-keto acid using (R)-MAAO, 
which reacts exclusively with the (R)-amino acid. This resulting α-keto acid was later converted to its 
(S)-antipode with an (S)-aminotransferase and aspartate as the amine donor, yielding the enantiopure 
product in 66% isolated yield. On the other hand, the deracemization of the racemic amino acid was 
achieved using (R)-MAAO in combination with a chemical reduction of the imine intermediate using 
the ammonia borane complex that regenerates the racemic amino acid whilst the enantiopure (S)-amino 
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acid accumulates (79% isolated yield). Finally, the combination of this (R)-MAAO and an (S)-amino 
acid dehydrogenase/ammonium formate/NADH system was used to obtain the enantiopure (S)-amine 
in 68% conversion and 54% isolated yield. 
 
Scheme 16. Deracemization strategies for the synthesis of a valuable (S)-amino acid using a 
monoamino acid oxidase from Trigonopsis variabilis. 
 
Interestingly, Kroutil and co-workers recently reported the combined use of freeze-dried E. coli cells 
containing overexpressed L-amino acid oxidases or L-amino acid deaminases (L-AAD) with selective 
reductases to transform prochiral -keto acids into optically active -hydroxy acids (Scheme 17).86 
The best results were found with the L-AAD from Proteus myxofaciens providing six different -keto 
acids, which were later stereoselectively reduced with L- or D-isocaproate reductases (HicDHs) from 
Lactobacillus paracasei DSM 20008 (L-Hic) and Lactobacillus confuses DSM 20196 (D-Hic). Twelve 
-hydroxy acids were obtained with excellent selectivities and conversions, including enantiopure 4-
hydroxyphenyl lactic acid, an interesting building block for the preparation of compounds with 
medicinal interest such as anti-diabetic Saroglitazar, Aeruginosins 298A, peroxime proliferator 
activated / agonists, Microcin SF608, and others. 
 16 
 
Scheme 17. Multi-step enzymatic synthesis of -hydroxy acids including enantiopure 4-hydroxyphenyl 
lactic acid. 
Berberine bridge enzymes (BBEs) are redox enzymes that catalyze the anaerobic oxidative carbon-
carbon bond formation, transforming benzylisoquinolines to berberines. The action of BBE from 
Eschscholzia californica heterologously expressed in E. coli. for the asymmetric chemoenzymatic 
synthesis of interesting alkaloids such as (S)-Scoulerine and (R)-Reticuline was reported by Kroutil and 
co-workers.87 (S)-Scoulerine belongs to the family of berbines, a group of compounds with diverse 
biological profiles such as analgesic, anti-inflammatory, hypnotic or sedative properties. (R)-Reticuline 
is inside the 1-benzyl-1,2,3,4-tetrahydroisoquinoline group and has interesting anti-spasmodic and 
hypotensive properties. The oxidative KRs of racemic Reticuline and other substituted 1-benzyl-
1,2,3,4-tetrahydroisoquinolines were possible with complete selectivity at 40 ºC for 24 h by using 
crude catalase for the consumption of any hydrogen peroxide generated (Scheme 18). 
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Scheme 18. BBE-catalyzed oxidative KRs of racemic 1-benzyl-1,2,3,4-tetrahydroisoquinolines 
including the synthesis of (S)-Scoulerine and (R)-Reticuline. 
 
2.4. Laccases. 
Laccases are blue multi-copper oxidases able to catalyze mild oxidative transformations. The actions of 
laccases are usually accomplished by combination with a laccase mediator system (LMS) in the 
presence of molecular oxygen that is reduced to water, providing a green access to different families of 
compounds.88I Ideal redox mediators are good laccase substrates whose oxidized and reduced forms 
are stable without inhibiting the enzymatic reaction. 
Because of their high stability and selectivity for phenolic substrates, their applications in sustainable 
synthetic routes have received great attention in recent years.89 For instance, seven Resveratrol 
oligomers with anti-proliferative activities have been produced by oxidative coupling of their 
monomeric forms using the laccase from Trametes versicolor.90 These stilbenoids were converted into 
the corresponding dehydrodimers incorporating a dihydrobenzofuran moiety as major products with 
regio- and diasteroselectivity but no enantioselectivity (Scheme 19). The reactions were carried out in a 
biphasic system composed of ethyl acetate (EtOAc) and a phosphate buffer pH 4.7 at room 
temperature, leading to the racemates which were later separated in their enantiomers by repeating 




Scheme 19. Trametes versicolor laccase-catalyzed dimerization of Resveratrol monomers. 
 
The synthesis of aminonaphtoquinones with anti-cancer activity has been possible by laccase-catalyzed 
C-N bond formation.91 Nuclear monoamination of a 1,4-naphthohydroquinone using 2 equiv. of 
primary aromatic amines with commercially available Novozyme 51003 laccase from the thermophilic 
ascomycete Myceliophthora thermophile, led to the formation of the final products in low to high 
yields (Scheme 20). Limited improvements were found at pH 6 and with DMF as cosolvent to favor the 
solubility of the starting materials. 
 
Scheme 20. Laccase-catalyzed synthesis of aminonaphthoquinones by nuclear amination of 1,4-
naphthohydroquinones. 
 
Together with other oxidases and oxygenases, laccases have also allowed the development of selective 
modifications in steroids.92 For instance, Riva and co-workers reported the unexpected C-4 
hydroxylation of ergot alkaloids.93 In addition, laccases can be coupled to the action of 
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dehydrogenases in order to find effective conditions for the nicotinamide cofactor recycling. This is the 
case of the purified Toxicodendron pubescens laccase using the redox mediator Meldola’s blue (7-
dimethylamino-1,2-benzophenoxazine). This has been used in combination with the 7-
hydroxystereoid dehydrogenase for the gram scale oxidation of cholic acid and its corresponding 
methyl ester to the 7-keto derivatives in up to 70% yield, using a phosphate buffer pH 6.5 or a biphasic 
system with isopropanol as cosolvent, and oxygen as mild oxidant.94 
 
2.5. Oxygenases. 
This type of enzyme catalyzes the incorporation of molecular oxygen into a molecule, giving access to 
oxygenated compounds in a sustainable and safe manner in comparison with traditional chemical 
methods.95,96 Oxygenases usually act with excellent regio- and stereoselectivity, the functionalization 
of non activated substrates such as alkanes, alkenes and aromatic compounds being possible.97-99 In 
this context, the action of some cyctochromes P450 (CYPs),100-104 Baeyer-Villiger monooxygenases 
(BVMOs),105-109 and toluene dioxygenases (TDOs), is remarkable.110 
The main limitations in these reactions reside in the low substrate concentration employed, the low 
catalytic activity, and their limited availability, the addition of an external cofactor and other enzymes 
being required for the development of an efficient transformation. The development of recombinant 
and evolved enzymes rather than the use of native proteins has provided better access to organic 
compounds with interesting biological profiles. This is the case, for instance, in the synthesis of 
different drugs using CYPs,111-113 Flavin MOs114 and TDOs.115-118 Nevertheless, in some cases 
whole cell or purified oxygenases have been used for synthetic purposes aimed at the production of 
compounds with interesting biological activities. Bernhardt and co-workers described the use of the 
cytochrome P450 monooxygenase CYP106A2 from Bacillus megaterium ATCC 13368 in whole-cell 
form for the hydroxylation of variety of 3-oxo-4-steroids such as progesterone and 
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deoxycorticosterone at the 15-position, and the use of abietic acid, which displays interesting anti-
allergic, anti-inflammatory and anti-convulsant properties, at the 12-position to obtain an / mixture 
with moderate stereodiscrimination (Scheme 21).119 
 
Scheme 21. Regio- and setereoselective hydroxylation of abietic acid at the 12-position. 
 
Streptomyces griseus ATCC13273 and DSM40236 were found to be active microorganisms for the 
production of hydroxylated Flurbiprofen derivatives, which possess potential anti-inflammatory 
activities, the presence of methyl transferase activity also being found due to the formation of a 
methoxy analogue (Scheme 22).120 In addition, two new fluorometabolites, flurbiprofenamide and 7-
hydroxy-flurbiprofenamide, formed via the action of an amidotransferase, were detected in culture 
extracts of Streptomyces lavenduligreseus and Streptomyces rimosus used as resting cells in the 
presence of different nitrogen sources. 
 
Scheme 22. Regioselective hydroxylation of Flurbiprofen by using Streptomyces griseus strains. 
 
A fungal strain from Mucor piroformis has catalyzed the regio- and stereoselective functionalization of 
(Z)--santalyl acetate into four novel metabolites identified as 10,11-cis--epoxy--santalol, 5-
hydroxy-(Z)--santalol, 10,11-dihydroxy--santalol, and 5--hydroxy-10,11-cis--epoxy--santalol 
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(Scheme 23).121 The transformations initially failed using (Z)--santalol as staring material due to its 
potent anti-fungal activity, so its acetate was synthesized and then successfully tested in 
biotransformations with a series of fungi, involving the same alcohol in the medium as intermediate. 
 
Scheme 23. Oxygenation of (Z)--santalyl acetate using a fungal strain from Mucor piroformis. 
 
3. Use of lyases for the synthesis of chiral drugs. 
Enzymatic carbon-carbon bond formation reactions have received considerable attention because of the 
high stereoselectivity displayed by lyases.122,123 Among this family, aldolases and hydroxynitrile 
lyases are without doubt the most versatile enzymes for synthetic transformations, although in recent 
years other biocatalysts have appeared as useful tools.124,125 The role of aldolases and hydroxynitrile 
lyases in the synthesis of pharmaceuticals will now be discussed. 
 
3.1. Aldolases. 
This class of enzymes catalyze aldol reactions creating carbon-carbon bonds in a highly stereoselective 
manner, providing access to adducts where a chain elongation of two or three carbon units have 
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occurred, in addition to the appearance of one or two new stereocenters.126 Importantly, this enzymatic 
approach allows the formation of a single diastereoisomer after only one reaction step. Chemists have 
taken advantage of previously described aldolase-catalyzed reactions to synthesize interesting sugar 
derivatives with high stereoselectivity, such as Digitoxin, an active glycoside prescribed for patients 
with cardiac diseases that is composed of a steroid part and a trisaccharide.127 In recent years, the 
action of novel aldolases with improved catalytic properties has been described. Advances in enzyme 
engineering techniques nowadays open a myriad of possibilities for the creation of mutants with 
broader substrate specificity, facilitating the development of more efficient transformations.128 
The D-Fructose-6-phosphate aldolase from Escherichia coli (FSA) used as a lyophilized powder is a 
valuable enzyme that catalyzes the addition of dihydroxyacetone and hydroxyacetone to aldehydes, 
giving access to a large family of sugar derivatives with important applications in medicinal chemistry, 
such as 1-deoxynojirimycin (DNJ), 1-deoxymannojirimicyn (DMJ), 1,4-dideoxy-1,4-imino-D-
arabinitol, 1,4,5-trideoxy-1,4-imino-D-arabinitol and 1-deoxy-D-xylulose, among others.129 For 
instance, DNJ and DMJ were obtained by FSA-catalyzed reaction of dihydroxyacetone with (N-Cbz-
amino)-2-hydroxypropanal enantiomers, leading to DNJ in 49% yield and DMJ in 14% after 40 h and 
the addition in portions of the aldehyde at 25 ºC (Scheme 24). 
 
Scheme 24. Synthesis of polyhydroxylated sugars DNJ and DMJ by using D-Fructose-6-phosphate 
aldolase in the addition of dihydroxyacetone to (N-Cbz-amino)-2-hydroxypropanal. 
 
The same research group has reported the synthesis of other polyhydroxylated families of compounds. 
For instance, an optimization study of the aldolase-catalyzed reaction was performed for the subsequent 
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production of pyrrolidine derivatives that were evaluated as glycosidase inhibitors.[130] The reaction 
between N-Cbz aminoaldehydes and dihydroxyacetone phosphate (DHAP) occurred with variable 
yields and selectivity values, leading to different diastereoisomers depending on the aldolases 
employed in the process. In all cases, D-fructose-1,6-biphosphate aldolase from rabbit muscle 
(RAMA), L-rhamnulose-1-phosphate aldolase (RhuA) and L-fuculose-1-phosphate aldolase (FucA), 
led to the final products with an excellent stereocontrol (Scheme 25). 
 
Scheme 25. Synthesis of polyhydroxylated pyrrolidine derivatives using aldolase-catalyzed additions 
of DHAP to N-Cbz aminoaldehydes. 
 
The chemoenzymatic syntheses of pyrrolizidine derivatives such as Casuarine stereoisomers have been 
described through a two-step route. These nitrogenous compounds possess interesting biological 
profiles, acting as -glucosidase inhibitors. The approach consisted in the aldolase-catalyzed addition 
of DHAP to N-Cbz-aminoethanal, furnishing 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) and its 
enantiomer LAB, followed by subsequent one-pot chemical deprotection-reductive amination.131 In 
the first step, a FucA mutant was required, while the wild type from RhuA displayed excellent results 
for the synthesis of LAB. The use of a FSA mutant also allowed the preparation of other pyrrolizidine 
derivatives with good yields and selectivities.132 Indolizidines and quinolizidines are also 
conformationally restricted iminocyclitols, some of them acting as glycosidase inhibitors and 
possessing interesting therapeutic applications as anti-cancer, anti-diabetic, anti-metastatic, anti-viral 
and immunoregulating agents. Clapés and co-workers also reported the synthesis of these families of 
compounds through stereoselective carbon-carbon bond formation reactions. RhuA and FucA were 
identified as possible catalysts for aldol additions, although the use of evolved mutants led to better 
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results.133 
Lemaire and co-workers have efficiently obtained aminocyclitols that are also potent glycosidase 
inhibitors. The chemoenzymatic route involves two key enzymatic transformations. Firstly, Candida 
antarctica lipase type B (CAL-B) catalyzed the kinetic resolution of 1,1-dimethoxybut-3-en-2-ol in 
combination with vinyl acetate at room temperature, leading to the (S)-alcohol and the (R)-acetate in 
good optical purity. These were later transformed to the 1,1-dimethoxy-4-nitrobutan-2,3-diol 
enantiomers (Scheme 26).134 These building blocks were then reacted with DHAP in the presence of 
RAMA to produce the corresponding nitrocyclitols, the immediate precursors of the target 
aminocyclitols, in low yields but with excellent selectivity. 
 
Scheme 26. Synthesis of aminocyclitols using CAL-B and RAMA. 
 
Finally, the possibilities of aldolases to work in one-pot catalytic cascades, as reported by Wever and 
co-workers for the chemoenzymatic synthesis of D-fagomine, is worthy of comment.135 The key step 
involves the orchestral action of four enzymes occurring a phosphorylation, oxidation, carbon-carbon 
bond formation, and dephosphorylation, using dihydroxyacetone phosphate (DHAP)-dependent RAMA 
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for the aldol formation to give the desired carbohydrate fragment intermediate. 
 
3.2. Oxynitrilases. 
This class of lyases, also known as hydroxynitrile lyases (HNLs), catalyzes the addition of hydrogen 
cyanide (HCN) to aldehydes or methyl ketones,136 providing an efficient access to cyanhydrins, which 
are highly attractive building blocks in synthetic chemistry.137,138 In this context, the reaction of 
benzaldehyde with HCN allows the formation of mandelonitrile in optically active form, and this 
serves as an intermediate in the synthesis of the serotonin re-uptake inhibitors Fluoxetine, Atomoxetine 
and Nisoxetine. Nanda and co-workers used the crude Prunus armeniaca hydroxynitrile lyase 
(ParsHNL) from Himalayan apricot as biocatalyst and iPr2O as solvent for this transformation, 
affording the (R)-mandelonitrile in 92% yield and 98% ee (Scheme 63).139 In addition, the same 
enzyme catalyzed the addition of HCN to 2-thiophene-carboxaldehyde, yielding (S)-2-hydroxy-2-
(thiophen-2-yl)acetonitrile in 90% yield and 97% ee (Scheme 27). The latter is a valuable precursor in 
the synthesis of (R)-Duloxetine, a serotonin norepinephrine re-uptake inhibitor. 
 
Scheme 27. HNL-catalyzed synthesis of cyanhydrins as valuable precursors of serotonin re-uptake 
inhibitors. 
 
Similarly, the same research group reported the addition of HCN to hexanal also using the ParsHNL, 
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with 82% yield after 4 h of almost enantiopure (R)-2-hydroxyheptanenitrile. This served as an ideal 
building block in the synthesis of a series of metabolites from the family of nonanolides (Scheme 
28).140 Stagonolides are a class of naturally occurring nonenolides with interesting biological 
properties. Stagonolide-B has been obtained chemoenzymatically through the ParsHNL-catalyzed 
addition of HCN to butanal, which occurs in good yield to give (R)-hydroxypentanenitrile in the key 
asymmetric step of the synthesis (Scheme 28).141 
 
Scheme 28. HNL-catalyzed synthesis of cyanhydrins for the synthesis of macrolides. 
 
Venlafaxine hydrochloride in an anti-depressant currently commercialized as EffexorXR® and used for 
the treatment of depression and anxiety disorders. Its enantiomers having different profiles, the (R)-(+)-
enantiomer being a serotonin re-uptake inhibitor, while the (S)-(–)-enantiomer is a norepinephrine re-
uptake inhibitor, a fact that highlights the importance of their asymmetric synthesis. Nanda and co-
workers have reported the synthesis of (R)-(+)-Venlafaxine starting from the non asymmetric 
transcyanation of cyclohexanone in a 10 gram scale process catalyzed by the enzymatic extract of 
rubber tree HNL (Hevea brasiliensins, HbHNL).142 In this case a mild reagent such as acetone 
cyanohydrin was used. In addition, the synthesis of two other Venlafaxine analogues was achieved with 




Scheme 29. Chemoenzymatic synthesis of Venlafaxine analogues using Hevea brasiliensis 
hydroxinitrile lyase. 
 
4. Use of transferases for the synthesis of chiral drugs. 
Of the different types of transferases, transaminases have attracted special attention in recent years; 
they allow the production of chiral amines, which are compounds with multiple biological profiles that 
serve as building blocks for numerous families of compounds.143 Because of this, the development of 
enzymatic methods for this class of nitrogenous compounds is now highly appealing.144-147 The 
application of -transaminases is having an extraordinary influence on the development of academic 
and industrial processes, since it allows the oxidative resolution and deracemization of racemic 
amines.148 More excitingly, it also allows the transamination of prochiral ketones to afford optically 
active amines in a single step.149,150,151 These transformations require the addition of pyridoxal-5’-
phosphate (PLP) as cofactor for the effective action of the enzyme. In addition, the action of other 
enzymes are required to assure proper cofactor recycling and to avoid enzyme inhibition, the use of 
alanine dehydrogenase (Ala-DH), glucose dehydrogenase (GDH), lactate dehydrogenase (LDH), or 
others accompanying the main transamination reaction.149 
The development of evolved transaminases has allowed the design of efficient transformations, greatly 
improving their substrate specificity, as well as the ability to accept highly hindered substrates such as 
esteroids152 or complex organic molecules.153,154 In this context, it is worth mentioning the work of 
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Savile et al. in the synthesis of the anti-diabetic (R)-Sitagliptin. Savile's research has been awarded a 
number of prestigious prizes after evolving an enzyme from non initial activity.155 
Remarkably, transaminases are also involved in cascade reactions via a perfect combination with other 
enzyme sources such as alcohol dehydrogenases,156 synthases157 and pyruvate decarboxylases158 
which have served for the production of interesting Vanillin and Ephedrine derivatives. Here, we have 
focused on the application of native enzymes, and so evolved transaminases and those of unknown 
origin, mainly those commercialized by biotechnological companies and named with their own 
acronyms, have not been included. Examples of the production of pharmacologically relevant 
compounds by using asymmetric transaminase-catalyzed reactions are described here. 
Silodosin is a single enantiomer prodrug with (R)-configuration used in the treatment of urinary 
diseases. A key Silodosin intermediate has been obtained recently by the oxidative resolution of the 
racemic amine or transamination of the corresponding ketone, good levels of activity and 
stereodiscrimination being found with different lyophilized E.coli cells containing overexpressed -
TAs.159 In both cases 10% of DMSO as cosolvent was required for the solubilization of the starting 
materials. For the kinetic resolution of the amine, (R)-Arthrobacter sp. and Bacillus megaterium 
displayed the best results, acting with opposite selectivities (Scheme 30). Since the (R)-amine 
enantiomer was obtained in good yield, the -TA from (R)-Arthrobacter sp. provided the best access to 
the desired intermediate in quantitative conversion and perfect optical purity by a transamination 
approach (Scheme 30). 
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Scheme 30. Chemoenzymatic synthesis of Silodosin by oxidative resolution or transamination using 
different transaminases. 
 
The asymmetric synthesis of Ramatroban, an anti-allergic drug also used for the treatment of coronary 
diseases, has been achieved by transamination of a ketone precursor.160 The 2,3,4,9-tetrahydro-1H-
carbazol-3-amine isomers were successfully obtained using the transaminase from Chromobacterium 
violaceum (Cv--TA) in lyophilized form for the (S)-enantiomer (Scheme 31), while for the (R)-
enantiomer a semi-purified mutant of (R)-Arthrobacter led to the best results. This synthetic route 
seems to be more efficient in terms of E-factor, isolated yield, reaction time and the number of steps 
than the previous chemoenzymatic approach described using lipases. Inside the indazoyl class, a potent 
calcitonin gene-related peptide (CGRP) receptor antagonist has been synthesized finding Bacillus 
thuringiensis as an effective enzyme for the production of a key intermediate.161 Better results in terms 
of productivity and reaction time were achieved when the commercial available enzyme was purified, 
cloned and expressed in E. coli. 
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Scheme 31. Chemoenzymatic synthesis of (R)-Ramatroban using transaminases. 
 
An example of chemoenzymatic synthesis of anti-cholinergic agent (S)-Rivastigmine has been already 
described in this review using a bioreduction approach.57 The synthesis of this active pharmaceutical 
ingredient (API) has been elegantly achieved by Kroutil and co-workers, -transaminases from Vibrio 
fluvialis (Vf--TA)162 and Parococcus denitrificants (Pd--TA)163 proving to be very efficient 
enzymes in the transamination of the corresponding ketone precursor using L-alanine as amine donor. 
The transamination of an O-protected ketone occurred in complete conversion and excellent selectivity 
using Vf--TA, while Pd--TA allowed the transamination of the corresponding ketone including the 
required carbamate functionality in metha-position (Scheme 32). 
 
Scheme 32. Chemoenzymatic synthesis of (S)-Rivastigmine using transaminases. 
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After an exhaustive screening of 60 enzymes, the (S)-1-(5-fluoropyrimidin-2-yl)-ethylamine, an 
important intermediate in the synthesis of JAK2 kinase inhibitor AZD1480, has been obtained using 
Vf--TA as biocatalyst and -methylbenzylamine as amine donor in the transamination of the 
corresponding ketone (Scheme 33).164,165 Optimization of the reaction conditions led to the successful 
scale-up of the multi-gram Vf--TA in whole cell form or using the commercially available alternative. 
 
Scheme 33. Multi-gram Vf--TA-catalyzed transamination reaction for the synthesis of an AZD1480 
precursor. 
 
Valinol is a highly versatile 1,2-amino alcohol with applications as a chiral shift agent, a building block 
for pharmaceuticals and in organocatalytic reactions. Its synthesis has been achieved by transamination 
of 1-hydroxy-3-methylbutan-2-one in water-saturated organic solvents, or in pure aqueous medium.166 
The best results were found with lyophilized E.coli cells containing overexpressed transaminases from 
(R)-Arthrobacter sp., Aspergillus terreus, Gibberella zeae and Neosartoria fischeri for the production 
in high to complete conversions of the (S)-enantiomer, while Bacillus megaterium seemed to be the 
most efficient enzyme for the production of the antipode in 98% yield (Scheme 34). 
 




Finally, in this section it is worth mentioning the ability of transaminases for the regio- and 
stereoselective monoamination of diketones. This has allowed the production of all of the possible 
diastereoisomers of 2,6-substituted piperidines, versatile building blocks in the synthesis of 
alkaloids.167-169 The adequate selection of an active and selective transaminase allowed the 
monoamination of one of the keto groups, which immediately cyclized in the reaction medium to afford 
the corresponding imines (Scheme 35). Their reduction using palladium-catalytic hydrogenation led to 
interesting structures such as the natural alkaloid (+)-dihydropynidine, its enantiomer and both 
diastereoisomers (R= propyl), or isosolenopsin stereoisomers (R= n-C9H19). 
 
Scheme 35. Stereoselective transaminase-catalyzed monoamination of 1,5-diketones for the production 
2,6-substituted piperidine diastereoisomers. 
 
5. Conclusions. 
Nowadays, the pharmaceutical industry faces significant challenges and must take advantage of the 
enzyme toolbox for the development of efficient transformations.170-173 The application of enzymes 
has taken on an extraordinary importance over the last decades in the development of efficient and 
sustainable transformations with a high level of selectivity,174-177 a one-pot combination with chemical 
catalysis also being possible for the production of a desired target in high purity, yield and 
stereoselectivity.178 Native hydrolases, oxidoreductases, transferases and lyases have demonstrated 
their versatility in synthesis over the years, although there is still a big gap for ligases and 
isomerases.179 However, novel enzymes such as imine reductases180,181 are emerging at an 
exponential rate, and are attracting considerable attention nowadays,182-184 thanks in particular to the 
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rational design of proteins by directed evolution techniques.185-188 Because of all this, it is clear that 
biocatalysis has still a long way to go and will continue helping organic chemists improve existing 
synthetic strategies and develop valuable, novel products both for drug design and, importantly, for 
other sectors of industry. 
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